Your browser is no longer supported. Please, upgrade your browser.
Settings
UBX [NASD]
Unity Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.88 Insider Own5.00% Shs Outstand52.48M Perf Week5.30%
Market Cap387.27M Forward P/E- EPS next Y-1.92 Insider Trans-39.22% Shs Float48.13M Perf Month23.01%
Income-92.30M PEG- EPS next Q-0.47 Inst Own60.90% Short Float5.02% Perf Quarter15.57%
Sales- P/S- EPS this Y30.30% Inst Trans7.84% Short Ratio2.56 Perf Half Y143.38%
Book/sh1.87 P/B3.93 EPS next Y12.30% ROA-56.90% Target Price5.83 Perf Year18.93%
Cash/sh2.51 P/C2.93 EPS next 5Y- ROE-84.60% 52W Range2.72 - 15.44 Perf YTD40.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.40% Beta-
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low170.22% ATR0.65
Employees76 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)51.42 Volatility7.63% 9.31%
OptionableYes Debt/Eq0.25 EPS Q/Q-3.90% Profit Margin- Rel Volume0.42 Prev Close7.35
ShortableYes LT Debt/Eq0.25 Earnings- Payout- Avg Volume942.89K Price7.35
Recom3.20 SMA20-3.20% SMA5010.51% SMA20016.64% Volume223,539 Change0.00%
Feb-16-21Downgrade Citigroup Neutral → Sell $5 → $6
Aug-18-20Downgrade Morgan Stanley Overweight → Equal-Weight $5
Aug-18-20Downgrade Mizuho Buy → Neutral $33 → $4
Aug-18-20Downgrade Citigroup Buy → Neutral $31 → $5
Aug-17-20Downgrade ROTH Capital Buy → Neutral
Jul-28-20Initiated ROTH Capital Buy $35
Dec-12-19Initiated Cantor Fitzgerald Overweight $20
Mar-07-19Initiated Cantor Fitzgerald Overweight $21
Sep-07-18Initiated Mizuho Buy
May-29-18Initiated Morgan Stanley Overweight $25
May-29-18Initiated Goldman Neutral $17
May-29-18Initiated Citigroup Buy $32
Feb-26-21 04:05PM  
Feb-24-21 08:00AM  
Feb-08-21 08:00AM  
Feb-03-21 08:00AM  
Feb-01-21 08:00AM  
Jan-12-21 10:44AM  
Dec-22-20 07:45AM  
Dec-16-20 08:00AM  
Dec-14-20 07:00AM  
Dec-02-20 10:56AM  
Nov-04-20 04:01PM  
Oct-12-20 08:00AM  
Sep-15-20 08:00AM  
Sep-04-20 08:00AM  
Aug-31-20 04:05PM  
Aug-25-20 08:39AM  
Aug-18-20 09:21AM  
Aug-17-20 01:49PM  
11:32AM  
11:12AM  
07:00AM  
Aug-04-20 04:05PM  
Jul-31-20 07:57AM  
Jul-29-20 04:05PM  
Jul-24-20 08:00AM  
Jul-06-20 05:00PM  
Jul-02-20 08:21AM  
Jul-01-20 04:05PM  
Jun-11-20 02:32PM  
Jun-08-20 09:04AM  
Jun-05-20 01:11PM  
May-28-20 04:05PM  
May-07-20 04:05PM  
May-04-20 04:30PM  
Apr-27-20 11:06AM  
Apr-20-20 08:24AM  
Mar-31-20 04:05PM  
Mar-30-20 05:20PM  
Mar-11-20 04:05PM  
Mar-03-20 04:05PM  
Mar-02-20 04:30PM  
Feb-25-20 06:00AM  
Feb-24-20 04:05PM  
Jan-30-20 01:49PM  
Dec-22-19 05:09PM  
Nov-06-19 04:05PM  
Oct-31-19 02:14PM  
08:00AM  
Oct-24-19 08:00AM  
Oct-23-19 03:29PM  
08:00AM  
Sep-20-19 08:00AM  
Aug-27-19 08:00AM  
Aug-23-19 12:50PM  
Aug-22-19 10:09AM  
Aug-07-19 04:05PM  
Jul-30-19 04:30PM  
08:00AM  
Jun-18-19 02:47PM  
07:00AM  
May-30-19 07:33AM  
May-29-19 04:05PM  
May-23-19 04:01PM  
09:19AM  
May-22-19 07:21AM  
May-11-19 10:43AM  
May-08-19 04:05PM  
Apr-29-19 04:05PM  
Mar-06-19 08:00AM  
Mar-04-19 04:05PM  
Feb-27-19 04:05PM  
Feb-25-19 04:05PM  
Jan-23-19 07:22AM  
Jan-22-19 04:05PM  
Jan-08-19 07:00AM  
Jan-03-19 04:52PM  
Dec-05-18 10:35AM  
08:46AM  
Dec-04-18 08:00AM  
07:59AM  
Dec-03-18 05:30PM  
Nov-13-18 08:00AM  
Nov-07-18 04:05PM  
Oct-31-18 04:05PM  
Oct-01-18 01:34PM  
Sep-24-18 04:05PM  
Sep-20-18 02:59PM  
Sep-17-18 08:00AM  
Sep-14-18 09:53AM  
Sep-13-18 02:46PM  
Sep-05-18 04:05PM  
Aug-29-18 09:39AM  
Aug-09-18 04:05PM  
Jul-31-18 04:05PM  
Jul-13-18 02:45PM  
Jun-25-18 08:00AM  
Jun-13-18 04:00PM  
07:20AM  
Jun-07-18 05:00PM  
Jun-05-18 04:05PM  
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
David Nathaniel EPresidentDec 16Sale5.241,700,0008,908,000624,703Dec 18 05:14 PM
David Nathaniel EPresidentJun 05Buy8.903,20028,4782,327,186Jun 09 04:44 PM